Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty biopharmaceutical company that provides high quality, lower-cost solutions for patients, physicians, and healthcare organizations in the multi-billion dollar therapeutic areas of respiratory disease and allergies. The Company’s first approved product, SYMJEPI (epinephrine) Injection is an epinephrine injection pre-filled syringe product for use in the emergency treatment of anaphylaxis. Adamis is also currently developing other specialty pharmaceutical product candidates including APC-1000, an HFA inhaled nasal steroid product for the potential treatment of asthma; APC-6000, a naloxone injection for the potential treatment of opioid overdose; APC-4000, fluticasone with a DPI propellant for the potential treatment of asthma and APC- 8000, tadalafil sublingual disintegrating tablet for the potential treatment of erectile dysfunction. With the rising costs of healthcare in recent years, Adamis has been focusing on creating low-cost therapeutic alternatives in large markets in order to grow its business and to make treatments more affordable for more people. Adamis will pursue the 505(b)(2) regulatory approval filings with the FDA whenever possible in order to minimize costs and shorten the time to market. With its lead pipeline product and specialty pharmaceutical pipeline, ADMP is poised to become a leader in the specialty biopharmaceutical industry. Source
